Skip to main
ABT

Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Labs (ABT) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 45%
Buy 55%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abbott Laboratories is expected to see continued growth in their Diabetes Care division due to the demand for continuous glucose monitors (CGMs), potential expansion in the market, and planned product launches and manufacturing expansion. The company also has a strong Medical Device and Diagnostics portfolio, with double-digit EPS growth and a focus on high-growth areas such as electrophysiology and cancer diagnostics. Strategic investments and a diverse board and management team are expected to drive future growth, but there are potential risks to their price target and rating.

Bears say

Abbott Laboratories is facing some challenges in their Nutrition and Established Pharmaceuticals segments, with declining sales and pricing actions impacting their performance. While the company has a strong commitment to investing in growth and increasing shareholder value, they are also subject to strict product requirements and potential product recalls. Additionally, ABT is focused on promoting diversity and sustainability, which could further impact their financial performance in the short term.

Abbott Labs (ABT) has been analyzed by 20 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 55% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abbott Labs (ABT) Forecast

Analysts have given Abbott Labs (ABT) a Buy based on their latest research and market trends.

According to 20 analysts, Abbott Labs (ABT) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $124.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $124.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abbott Labs (ABT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.